23 October 2026 America's Small Business Network (ASBN) | October 23, 2026 Mammogen CEO and Co-Founder Liz Cormier-May was featured on ASBN's The Female Founder Show, discussing the company's mission to advance breast cancer detection through innovative RNA-based blood testing. During the interview, Cormier-May highlighted the challenges women with dense breast tissue face with traditional mammography and explained how Mammogen's genTRU-breast™ blood-based assay is being developed to provide additional information that could support earlier detection. Cormier-May also shared the personal experiences behind Mammogen's founding, the challenges of advancing innovation in women's health, and her advice for aspiring female entrepreneurs. Click Here to Read the Full Article and Watch the Interview →

Rockford News First | October 9, 2026 Rockford News First featured Mammogen CEO Elizabeth Cormier-May in a news segment discussing the growing role of blood-based testing in cancer detection. During the interview, Cormier-May explains how Mammogen is using RNA-powered technology to support earlier breast cancer detection, particularly for women with dense breast tissue. She also discusses how blood-based diagnostics could complement traditional mammography and help make cancer screening more accessible. Click Here to Watch the Full News Segment →

YouTube | Video Interview Mammogen founder Marty Keiser discusses the evolving diagnostics industry and the challenges facing companies that depend on insurance reimbursement and traditional payer models. The conversation explores the changing healthcare landscape and what these shifts could mean for diagnostics companies as they work to bring innovative technologies to market. Click Here to Watch the Full Interview →

NBC 10 News featured Mammogen CEO Elizabeth Cormier-May in its coverage of the evolving landscape of blood-based cancer detection and an upcoming FDA advisory committee review of GRAIL’s Galleri test. Cormier-May shared her perspective on the significance of liquid biopsy technology and discussed how Mammogen’s approach differs by focusing specifically on earlier breast cancer detection. The story also highlights Mammogen’s blood-based test and its potential role in supporting women who may need additional testing following their annual mammogram. Read the full article on NBC 10 News →

Explore RNA-powered diagnostics for breast cancer. Get checked today for better early detection!